Nasus Pharma Ltd. (NYSE: NSRX) announced results from its Phase 2 clinical study of NS002, an intranasal epinephrine powder formulation ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE